Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
50.04 ^CNY	+0.89%		+2.60%	-4.96%

Apr. 24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 24	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 24	CI
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	Jan. 26	MT
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	Dec. 12	MT
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	Dec. 04	MT
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	Nov. 09	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	23-10-12	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	23-09-18	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	23-09-18	CI
Gan & Lee Pharma Advances Trial of New Insulin Product	23-09-13	MT
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	23-07-20	MT
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	23-06-20	MT
Pharmaktiv acquired remaining 51% stake in Endogenix LLC from Gan & Lee Pharmaceuticals..	23-06-13	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
FDA Accepts Gan & Lee Pharma's Application for Insulin Glargine Injection	23-02-24	MT
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from S&P Global BMI Index	22-12-19	CI
Gan & Lee Pharmaceuticals.(XSSC:603087) dropped from FTSE All-World Index	22-12-12	CI
Gan & Lee Pharmaceuticals' Insulin Injection Enters Pakistani Market	22-12-09	MT
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from Shanghai Stock Exchange 180 Value Index	22-12-09	CI
Gan & Lee Pharmaceuticals.(SHSE:603087) dropped from SSE 180 Index	22-12-09	CI
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Gan & Lee Pharma Co-Founder to Buy $111 Million More Shares; Shares Up Nearly 6%	22-10-25	MT

Chart Gan & Lee Pharmaceuticals.

Duration

Period

More charts

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Gan & Lee Pharmaceuticals.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

50.04 CNY

Average target price

58 CNY

Spread / Average Target

+15.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
GAN & LEE PHARMACEUTICALS.	-4.96%	4.08B
CSL LIMITED	-3.79%	87.06B
SAMSUNG BIOLOGICS CO.,LTD.	+1.45%	40.25B
BIOGEN INC.	-15.94%	31.09B
UCB	+52.66%	24.74B
BIOMARIN PHARMACEUTICAL INC.	-14.50%	15.91B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
INCYTE CORPORATION	-14.38%	11.92B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+4.87%	8.73B

Biopharmaceuticals